Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. More Details
Flawless balance sheet and slightly overvalued.
Share Price & News
How has Aptose Biosciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: APS is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 21% a week.
Volatility Over Time: APS's weekly volatility has increased from 13% to 21% over the past year.
7 Day Return
1 Year Return
Return vs Industry: APS underperformed the Canadian Biotechs industry which returned -29.9% over the past year.
Return vs Market: APS underperformed the Canadian Market which returned 36.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Aptose Biosciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StCould The Aptose Biosciences Inc. (TSE:APS) Ownership Structure Tell Us Something Useful?
3 months ago | Simply Wall StAptose Biosciences Inc. (TSE:APS) Insiders Have Been Selling
4 months ago | Simply Wall StIs Aptose Biosciences Inc.'s (TSE:APS) Shareholder Ownership Skewed Towards Insiders?
Is Aptose Biosciences undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: APS (CA$5.78) is trading below our estimate of fair value (CA$161.26)
Significantly Below Fair Value: APS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: APS is unprofitable, so we can't compare its PE Ratio to the North American Biotechs industry average.
PE vs Market: APS is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate APS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: APS's PB Ratio (3.9x) is in line with the CA Biotechs industry average.
How is Aptose Biosciences forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: APS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: APS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: APS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if APS's revenue is forecast to grow faster than the Canadian market.
High Growth Revenue: Insufficient data to determine if APS's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if APS's Return on Equity is forecast to be high in 3 years time
How has Aptose Biosciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: APS is currently unprofitable.
Growing Profit Margin: APS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: APS is unprofitable, and losses have increased over the past 5 years at a rate of 32.8% per year.
Accelerating Growth: Unable to compare APS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15.5%).
Return on Equity
High ROE: APS has a negative Return on Equity (-54.79%), as it is currently unprofitable.
How is Aptose Biosciences's financial position?
Financial Position Analysis
Short Term Liabilities: APS's short term assets ($114.1M) exceed its short term liabilities ($5.4M).
Long Term Liabilities: APS's short term assets ($114.1M) exceed its long term liabilities ($420.0K).
Debt to Equity History and Analysis
Debt Level: APS is debt free.
Reducing Debt: APS had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: APS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: APS has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 24.5% each year.
What is Aptose Biosciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate APS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate APS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if APS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if APS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of APS's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
William Rice (61 yo)
Dr. William G. Rice, Ph.D., has been an Independent Director of Oncolytics Biotech Inc. since June 08, 2015. He has been the Chief Executive Officer and President of Aptose Biosciences Inc. since October 2...
CEO Compensation Analysis
Compensation vs Market: William's total compensation ($USD12.42M) is above average for companies of similar size in the Canadian market ($USD773.69K).
Compensation vs Earnings: William's compensation has increased whilst the company is unprofitable.
Experienced Management: APS's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: APS's board of directors are considered experienced (7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.6%.
Aptose Biosciences Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Aptose Biosciences Inc.
- Ticker: APS
- Exchange: TSX
- Founded: 1986
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$514.092m
- Shares outstanding: 88.94m
- Website: https://www.aptose.com
Number of Employees
- Aptose Biosciences Inc.
- 251 Consumers Road
- Suite 1105
- M2J 4R3
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/12 23:55|
|End of Day Share Price||2021/05/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.